Nobel laureate Carolyn Bertozzi joins Alnylam Pharmaceuticals Inc. board.

• Author: Wenger, Barbara

Alnylam Pharmaceuticals Inc. appointed Dr. Carolyn Bertozzi to its board. "We are thrilled to have Dr. Bertozzi's perspective on the board as Alnylam nears key milestones in our strategy. Dr. Bertozzi's technical and leadership expertise will help Alnylam in our goal to serve more patients than ever before," said Yvonne Greenstreet, Alnylam CEO.

Dr. Bertozzi is regarded as the founder of the bioorthogonal chemistry field and has cofounded multiple biopharmaceutical companies, including Palleon Pharmaceuticals, InterVenn, Grace Science LLC and Lycia Therapeutics. She was awarded the 2022 Nobel Prize in chemistry, jointly with Morten P. Meldal and Karl Barry Sharpless, "for the development of dick chemistry and bioorthogonal chemistry." She has been recognized with a MacArthur Fellowship, and is the first woman to receive the Lemelson-MIT Prize, the Welch Award in...